Abstract
Autophagy is a central component of integrated stress responses that influences many inflammatory diseases, including inflammatory bowel disease (IBD) and colorectal cancer (CRC). While the core machinery is known, the molecular basis of the epigenetic regulation of autophagy and its role in colon inflammation remain largely undefined. Here, we report that BRG1, an ATPase subunit of the SWI/SNF chromatin remodeling complex, is required for the homeostatic maintenance of intestinal epithelial cells (IECs) to prevent the inflammation and tumorigenesis. BRG1 emerges as a key regulator that directly governs the transcription of Atg16l1, Ambra1, Atg7 and Wipi2, which are important for autophagosome biogenesis. Defective autophagy in BRG1-deficient IECs results in excess reactive oxygen species (ROS), which leads to the defects in barrier integrity. Together, our results establish that BRG1 may represent an autophagy checkpoint that is pathogenetically linked to colitis and is therefore likely a potential therapeutic target for disease intervention.
Similar content being viewed by others
Introduction
Tissue inflammation inevitably results in tissue repair and tumorigenesis. Patients with inflammatory bowel disease (IBD), such as Crohn’s disease (CD) and ulcerative colitis (UC), exhibit a higher risk of developing colorectal cancer (CRC)1,2. IBD results from a complex series of interactions between the mucosal barrier, the environment, and the immune system3,4. Barrier integrity is essential for preventing invasion of microorganisms and development of chronic inflammations3,5. Thus, the defects in maintaining the homeostasis of intestinal epithelial cells (IECs) are known to trigger chronic inflammation and repair, which occasionally results in dysplasia6,7,8.
The integrated stress response (ISR) serves as a homeostatic mechanism that responds to and resolves various pathogenic insults in the gut9. Autophagy represents an intracellular lysosomal degradation system that ensures energetic homeostasis during metabolic stress and plays a protective role by removing damaged components from the cytosol10,11,12. The insufficient autophagy results in the accumulation of undesirable components that fuel inflammation, stimulate ROS, trigger cell death, and induce genomic instability, all of which cause the formation of the hallmarks of cancer10,13,14. In IECs, autophagy is implicated in intracellular bacterial killing, antimicrobial peptide secretion by Paneth and goblet cells, and the endoplasmic reticulum (ER) stress response in enterocytes6,11,15,16,17. Likewise, experiments using genetically engineered mouse models (GEMs) indicate that autophagy dysfunctions, such as ablation of Atg16l1, Atg5, or Atg7, stimulate immune responses, ROS production and ER stress6,11,18. Importantly, genome-wide association studies (GWAS) have uncovered single nucleotide polymorphisms in gene loci, including the autophagy-related proteins ATG16L1 and IRGM and the nucleotide-binding oligomerization domain-containing protein NOD2, which are closely associated with the risk of IBD19,20,21. Although autophagy is mainly seen as a cytoplasmic event, recent studies indicate that transcriptional and epigenetic regulation occurring in the nucleus intimately modulates autophagy22,23.
The SWI/SNF complex is a chromatin-remodeling complex that utilizes ATP hydrolysis to affect chromatin utilization24,25. The central ATPase in SWI/SNF complexes is either BRG1 (brahma-related gene 1; SMARCA4) or BRM (brahma; SMARCA2)24. BRG1 is characterized by a bromodomain and helicase/ATPase activity and influences a plethora of biological processes in both normal and neoplastic tissues24,26,27. The loss or mutation of BRG1 was initially identified in several cancers, including but not limited to lung cancer, ovarian cancer and Burkitt’s lymphoma28,29,30. However, other studies also report the positive effects of BRG1 on tumor initiation and progression31,32,33,34, suggesting that the roles of BRG1 in tumors depend on the cellular and genetic milieu. In the gut, previous studies indicate that BRG1 is essential for stem cell function in the small intestine, but not colons35. Study using mouse models of intestinal cancer (Apcmin/+) have shown that Brg1 knockout in the small intestine epithelium attenuates Wnt-driven tumor initiations34. In addition, early BRG1 loss impairs duodenum crypt-villous formation partially by regulating the Notch signaling36. Despite these advances regarding small intestine development and Wnt and Notch signaling regulation, functions of BRG1 in the colons remain largely undefined.
Recent work using targeted sequencing of UC samples with a high risk of developing colorectal carcinoma indicates that BRG1 is frequently mutated37, suggesting that BRG1 plays a potential role in inflammatory settings, such as colitis and colitis-CRC transformation. Thus, the present study focuses on determination of the adult function of BRG1 in resolving inflammation in a mouse model of colitis and colorectal tumorigenesis. Using loss- and gain-of-function approaches, we show that BRG1 ensures colonic homeostasis and coupled autophagy-dependent ROS reactions. Thus, our results highlight that BRG1 serves as a homeostatic checkpoint that inhibits inflammation-associated CRC.
Results
Epithelial BRG1 expression is reduced in IBD patients
Consistent with the previous reports, analyses of public datasets suggested that BRG1 mRNA was reduced in IBD specimens as compared with those in healthy controls (using datasets from NCBI’s Gene Expression Omnibus: GSE9452 and GSE3365; Fig. 1a). To validate these data in IBD, we performed quantitative RT-PCR (RT-qPCR) assays to determine BRG1 expression in colonic biopsy specimens from CD and UC patients as well as from normal controls. Compared with the levels in biopsies from healthy specimens, we showed that BRG1 mRNA levels were markedly decreased in the IBD biopsies (Fig. 1b). To expand upon these observations, we also performed immunohistochemistry analyses using a pre-valuated BRG1 antibody to characterize the BRG1 expression on the cellular level. The quantification of the immunohistochemical results revealed that the protein levels of BRG1 in the colonic epithelial cells were significantly lower in the IBD specimens relative to that in the healthy subjects (Fig. 1c). Together, these results suggest a causal link between BRG1 reduction and IBD pathogenesis.
Adult Brg1 IEC-AKO mice spontaneously develop colitis
The above results prompted us to utilize genetically engineered mouse models (GEMs) to define the potential importance of BRG1 in colonic inflammation. To assess the expression pattern of BRG1 in the intestine and colon, we performed co-immunofluorescence staining of BRG1 with Lgr5, ChgA, Muc2 and Lys, respectively, in the small intestine and colon of wild-type mice. BRG1+ cells were located along the intestinal epithelium and BRG1 was co-expressed with Lgr5, ChgA, Muc2 and Lys (Supplementary Fig. 1a), indicating that BRG1 is uniformly expressed both in the basal stem cells and differentiated cells. To circumvent the earlier developmental defects caused by Brg1 loss, we adopted VillinCre-ERT2/+ mice38 to ablate Brg1 at 2 months of age by tamoxifen administration (hereafter referred as Brg1IEC-AKO mice; deletion of Brg1 in adult IECs; Fig. 2a). Throughout the studies, Brg1flox/flox littermates treated with tamoxifen in the same cages were chosen as the control mice (referred as Brg1F/F). We found that the 4-month-old Brg1IEC-AKO mice displayed progressive diarrhea, and several mice exhibited rectal bleeding (2 months after the Brg1 deletion). As compared with Brg1F/F mice, 4-month-old Brg1IEC-AKO mice exhibited shorter colon lengths and obviously swollen spleen (Supplementary Fig. 1b, c). Further histopathological examinations verified that Brg1IEC-AKO mice developed spontaneous colitis, as evidenced by the presence of inflammatory infiltrates, crypt erosion, and the loss of tissue architecture (Fig. 2b). Weekly monitoring and histology quantification throughout the studies revealed no obvious abnormalities within 2 weeks of Brg1 deletion (Fig. 2b). However, the infiltrated immune cells and mild epithelium erosions were readily detected after one month of Brg1 ablation (Fig. 2b). Over time, the 4-month-old Brg1IEC-AKO mice (2 months after Brg1 deletion) exhibited severe transmural inflammation affecting the distal colon accompanied by crypt abscesses with nearly 100% penetrance. In contrast, none of the Brg1F/F littermates housed in the same cages displayed any signs of colonic inflammation. To confirm this observation, we quantified the immune cell infiltration by flow cytometry, and detected a substantial increase in the number of CD4+ T cells, macrophages and neutrophils in the colonic lysates from the 4-month-old Brg1IEC-AKO mice (Fig. 2c, Supplementary Fig. 1d). Similarly, the Brg1-deficient colons produced significantly higher levels of proinflammatory cytokines and chemokines than the colons of the control littermates (Fig. 2d). The excess inflammatory response occurring in the Brg1-deficient mice was associated with a loss of mucosa-producing goblet cells (colon and small intestine) and antimicrobial peptide (AMP)-producing Paneth cells (small intestine) (Fig. 2e, Supplementary Fig. 2e), which contribute to intestinal antibacterial defense by releasing antimicrobial factors. Further course studies revealed that 2 weeks of Brg1 ablation did not lead to appreciable changes in terms of the colonic stem cells or terminally differentiated cells (Supplementary Fig. 1f–i). However, the 12-week-old Brg1IEC-AKO mice began to exhibit a decrease in the number of Lgr5+ cells, goblet cells and Paneth cells (Supplementary Fig. 1g–i). Notably, the average life span of Paneth cells has been estimated to be ~60 days39, arguing that the reduced number of Paneth cells after 1 month of Brg1 depletion is likely due to the self-renewal defects. In addition, the numbers of other terminally differentiated cells, such as enteroendocrine cells and tuft cells in 12-week-old Brg1IEC-AKO mice were not significantly different in comparison to those in the control mice (Supplementary Fig. 1j, k)
To further define the role of BRG1 in colitis, we assessed the consequence of Brg1 loss in acute colitis by challenging the mice with dextran sodium sulfate (DSS), which is a chemical that induces experimental colitis with the clinical features of IBD. To this end, 2-month-old Brg1F/F and Brg1IEC-AKO mice were subjected to 3% DSS treatment, and susceptibility was subsequently monitored. We noticed that Brg1IEC-AKO mice exhibited hyper-susceptibility to DSS-induced colitis, and none of the Brg1IEC-AKO mice survived longer than 9 days of observations (Fig. 2f). Therefore, the mice were switched to a lower dose of DSS (1%) challenge. While the Brg1F/F mice did not display any observable phenotype changes or significant weight loss, the Brg1IEC-AKO mice exhibited severe colitis, as reflected by weight loss, colon shortening, a loss of goblet cells and Paneth cells, epithelial erosions and inflammatory response (Fig. 2g–i; Supplementary Fig. 2a, b). Meanwhile, Brg1 ablation did not lead to appreciable changes in terms of enteroendocrine cells and tuft cells (Supplementary Fig. 2c, d). Together, these results highlight that adult BRG1 plays a critical role in resolving inflammatory insults in the colonic epithelium.
Brg1 loss drives inflammation-associated CRC
The observation that Brg1IEC-AKO mice suffered from the sustained inflammation, prompted us to investigate the role of BRG1 in colitis-associated tumorigenesis. Therefore, we first treated the mice with a single dose of the DNA-methylating agent azoxymethane (AOM) to determine whether it enables the Brg1IEC-AKO mice to develop tumors. Five months after AOM treatment, the Brg1F/F mice did not grow any lesions as expected; however, all 7-month-old Brg1IEC-AKO mice developed at least two polyps within the colons (Fig. 3a). The histological examinations verified the presence of epithelium dysplasia in all ten Brg1IEC-AKO mice examined. Increased tumor incidences in Brg1IEC-AKO mice were associated with the persistent inflammation, as reflected by increased IL-6, IL-1β, TNFα and CCL2 productions in the 5 months of AOM-treated Brg1IEC-AKO mice (Fig. 3b). Together, these results highlight the notion that the chronic inflammation occurring in the Brg1IEC-AKO mice promotes epithelial dysplasia.
To substantiate this observation, we next induced CRC by injecting AOM, followed by three cycles of 1% DSS treatments. The changes in body weight were recorded throughout the duration of the DSS treatment, and the tumor burden was determined after 12 weeks of AOM treatment. As shown in Fig. 3c, the Brg1-deficient mice suffered from chronic inflammation and lost significantly more body weight than the Brg1F/F mice. Due to 1% DSS treatment, 4 out of 10 Brg1F/F mice did not develop any polyp, however, all Brg1-deficient mice at the same condition exhibited 100% penetrance of tumor development. Compared with the Brg1F/F mice, the polypoid lesions developed in Brg1IEC-AKO mice showed a threefold increase in the number, which were on average fourfold larger in size (Fig. 3d). Histological analysis revealed that the lesions developed in Brg1F/F mice were mainly graded as hyperplasia or low-grade dysplasia. Nevertheless, around 50% of polyps in Brg1-deficient colons were classified as high-grade dysplasia (Fig. 3e). Then, we analyzed cell proliferation and apoptosis in these tumors. Proliferation determined by Ki67+ cells, was slightly increased in the tumors in the Brg1IEC-AKO mice, whereas apoptotic cells (cleaved caspase-3 positive) did not differ significantly from those in the control mice (Fig. 3f). Thus, adult Brg1 ablation is strongly detrimental to the development and progression of inflammation-associated CRC, which is different from a previously reported Wnt-activated murine small intestinal model34.
BRG1 overexpression protects mice from colitis and CRC
Next we aimed to determine whether the elevated BRG1 expression could intimately protect the mice from colitis. Thus, we generated conditional BRG1-overexpressing mice (R26BRG1/+), which harbor a mini gene consisting of a CAGGS (a hybrid chicken β-actin and cytomegalovirus) promoter, a loxP-STOP-loxP (LSL) cassette and flag-tagged BRG1 cDNA knocked in the Rosa26 Locus (Fig. 4a). As characterized by immunohistochemistry and western blotting analyses, a three- to fourfold increase of BRG1 expression in IECs was achieved by the VillinCre/+-dependent recombination (VillinCre/+; Rosa26Brg1/+, hereafter referred as Brg1IEC-OE/+; Fig. 4b). During the 6-month follow-up, the Brg1IEC-OE/+ mice did not exhibit detectable abnormalities. In the intestines, the stem/progenitor cells and terminally differentiated cells (goblet cells, enteroendocrine cells and Paneth cells) displayed similar abundances between the R26Brg1/+ (control) and Brg1IEC-OE/+ mice (Supplementary Fig. 3a, b).
To induce acute inflammation, we challenged the mice with 3% DSS. Based on the weight loss, colon length and rectal bleeding, the Brg1IEC-OE/+ mice were more resistant to DSS-induced colitis as compared with R26Brg1/+ mice (Fig. 4c, d). As expected, histological analyses verified that there were fewer areas of ulceration and decreased lymphocyte infiltration in the BRG1-overexpressing colons (Fig. 4e). Similarly, the induction of proinflammatory cytokines and chemokines was markedly reduced in the 3% DSS-treated Brg1IEC-OE/+ mice relative to that in R26Brg1/+ mice (Fig. 4f). The weak inflammatory response occurring in the Brg1IEC-OE/+ mice was also associated with the increased numbers of goblet cells (colon and small intestine) and Paneth cells (small intestine) (Fig. 4g, Supplementary Fig. 3c). Importantly, we found that BRG1 overexpression rendered the mice to become more resistant to AOM/DSS-induced CRC. The pathological quantification verified that the number and size of tumors were markedly reduced in BRG1-overexpressing colons (Fig. 4h). Notably, following 3% DSS treatment, around 30% polypoid lesions developed in R26Brg1/+ mice were characterized as high-grade dysplasia. In sharp contrast, Brg1 overexpression largely curtailed the tumor development to hyperplasia and low-grade dysplasia (Fig. 4i). Together, these results establish that BRG1 overexpression protects the mice from DSS-induced epithelial damage and subsequent tumorigenesis.
BRG1 mediates ROS homeostasis to modulate barrier integrity
Considering that intestinal barrier dysfunctions frequently contribute to gut inflammation7,8,40, we investigated whether Brg1 loss compromised the barrier integrity by examining the distribution or expression of tight junction protein 1 (ZO-1), Claudin-1, and E-cadherin before the onset of the severe colitis (3-month-old mice examined). We assessed the distribution of the tight junction protein 1 (ZO-1) in Brg1F/F and Brg1IEC-AKO mice as a marker of tight junction structure. In contrast to the control specimens, the Brg1-deficient colons exhibited partially disrupted or discontinuous ZO-1 staining (Fig. 5a), indicating that an intact and functional mucosal barrier was compromised in Brg1IEC-AKO mice. In addition, expressions of other junction proteins, such as Claudin-1, E-cadherin, α-tubulins, and F-actin were also reduced in Brg1IEC-AKO mice (Fig. 5a, Supplementary Fig. 4a). These findings suggested that Brg1 ablation resulted in colonic leakage, as evidenced by the enhanced fluorescence in the serum of 3-month-old Brg1IEC-AKO mice fed with FITC-labeled dextran (4000 MW) (Fig. 5b). Thus, Brg1 silencing in adult colons leads to barrier disruption and colonic leakage.
Because epithelial cell death is among the major factors contributing to barrier integrity4,7,40,41, we therefore assessed the possible defects of cell survival in the Brg1IEC-AKO mice. Two weeks after tamoxifen treatment, Brg1 ablation (10-week-old mice) did not lead to appreciable changes in terms of cell death and proliferation (Supplementary Fig. 4b). However, as compared with the Brg1F/F mice, the numbers of TUNEL- and cleaved caspase-3-positive cells were significantly higher in the colonic sections of the 3-month-old Brg1IEC-AKO mice (Fig. 5c). Meanwhile, the number of Ki67-positive cells was slightly increased in the 3-month-old Brg1IEC-AKO mice, presumably due to ongoing regeneration compensated by epithelial proliferation (Fig. 5c). To prove that BRG1 directly influenced the cell survival, we isolated the IECs from the colons of Brg1flox/flox and VillinCre-ERT2; Brg1flox/flox mice, followed by 4-Hydroxytamoxifen (4-OHT) treatment to delete Brg1. The cells were referred as IECBrg1-F/F and IECBrg1-F/F; CreERT2, respectively. After 4 days of Brg1 deletion, we observed that Brg1 loss led to a profound increase at the expression levels of cleaved caspase-3 (C-C3) and cleaved PARP (Fig. 5d). Conversely, the apoptotic signal in the IECs isolated from the 5 days of DSS-treated Brg1IEC-OE/+ mice (IECBrg1-OE/+) was significantly lower relative to that in the control cells (IECBrg1/+) (Fig. 5d). We also established intestinal organoid cultures to further validate these results. As revealed by the 7-aminoactinomycin D (7-AAD) staining and cleaved caspase-3 immunostaining, the organoids lacking BRG1 displayed a substantial increase in apoptosis relative to the controls (Fig. 5e, f). Besides, the number of Ki67-positive cells was increased in organoids lacking BRG1 (Supplementary Fig. 4c). These results indicate that BRG1 is intrinsically required for the survival of IECs, whose defects might cause the barrier disruption and the subsequent inflammation.
To understand the mechanistic role of BRG1 in colonic homeostasis, we conducted an expression profile analysis using the IECs isolated from 7-week-old Brg1F/F and Brg1IEC-AKO mice, a time point at which Brg1 deletion did not led to colitis yet. Thus, expression alterations might reflect the primary effects of Brg1 loss in colons. Gene Ontology (GO) term analysis of the expression profile indicated no prominent changes of the genes related to apoptotic regulation. However, there was a significant enrichment of genes linked to oxidoreductase activity (Fig. 5g). To validate this finding, we stained 8-oxo-2′-deoxyguanosine (8-OHdG) to examine oxidative stress in colonic tissue and organoids, and detected that 8-OHdG level was indeed increased in the colons/organoids of 7-week-old Brg1IEC-AKO mice (Fig. 5h, Supplementary Fig. 4c). Oxidative stress is associated with CRC pathogenesis, and ROS plays an important role in apoptosis induction under both physiologic and pathologic conditions6,42. Therefore, we studied the role of ROS in BRG1-mediated inflammation by staining using 2′,7′-dichlorodihydrofluorescein diacetate (H2DCFDA), which is a fluorescent probe that reacts with ROS. To demonstrate a cell autonomous role of Brg1 in the ROS homeostasis, the IECs were isolated from Brg1flox/flox, VillinCre-ERT2; Brg1flox/flox or R26Brg/+, Brg1IEC-OE/+ mice, and Brg1 was similarly deleted by 4-OHT treatment. Flow cytometry analysis indicated that Brg1-deleted IECs (IECBrg1-F/F; CreERT2) produced significantly more amount of ROS relative to that in the IECBrg1-F/F cells, whereas the BRG1-overexpressing IECs (IECBrg1-OE/+) exhibited restrained ROS production (Fig. 5i). Similar to what we observed in the mice, the negative associations between BRG1 and the ROS signature were identified in the IBD clinical specimens (using datasets GSE11223, GSE3365, and GSE5795; Fig. 5j). Next, to clarify whether ROS elevation indeed led to apoptosis of Brg1-deficient IECs, we performed rescue assays by treatment of the Brg1-deficient IECs with an antioxidant, N-acetyl-l-cysteine (NAC). We found that NAC treatment reversed the cleaved caspase-3 signal to the levels similar to the control cells (Supplementary Fig. 4d), arguing that excess ROS indeed contributes to the survival defects of Brg1-deficient IECs.
To provide additional evidence that ROS is a necessary player in BRG1-mediated colitis, we conducted experiments to determine whether blocking ROS could reverse the inflammatory phenotype elicited by the Brg1 loss. To this end, 3-month-old Brg1F/F and Brg1IEC-AKO mice were treated with NAC for 1 month after the Brg1 was deleted at 2 months of age. As judged by colon length and H&E staining (Fig. 5k, l), the blockade of ROS via the administration of NAC in the Brg1IEC-AKO mice completely eased the severity of colitis, and the colonic histology was restored to the normal. Based on the expression levels of proinflammatory cytokines and chemokines, we found that the excess inflammatory response occurring in the Brg1IEC-AKO mice was largely alleviated by the ROS inhibition (Fig. 5m). In addition, the NAC treatment replenished the number of goblet and Paneth cells and relieved epithelial apoptosis to levels similar to those in the control mice (Supplementary Fig. 4e–g). Collectively, these data indicate that ROS plays a key role in BRG1-mediated colitis.
BRG1 serves as an autophagy checkpoint in IECs
To elucidate the molecular basis by which BRG1 modulated ROS, BRG1-bound chromatin from 2-month-old wild-type IECs was immunoprecipitated and analyzed by performing deep sequencing. The ChIP-seq analysis revealed that 12119 genes (26349 peaks) possessed BRG1 occupancies within 6 kb of annotated genes. The BRG1 binding intervals were located within the core transcribed portion of genes close to the transcription start site (TSS) (Supplementary Fig. 5a, b). To correlate the chromatin binding with the transcriptional regulation, the ChIP-seq data were aligned with the expression profile. The Venn diagrams indicated that 746 genes showed direct BRG1 occupancies and an expression downregulation upon Brg1 ablation (Fig. 6a). Among these genes, we noticed that the process of Autophagic vacuole fusion, Autophagic vacuole assembly and Autophagy was significantly enriched. As summarized by the heatmap, expression levels of central autophagy-regulatory genes, including Atg16l1, Atg7, Ambra1, Wipi2, were significant reduced in Brg1-deleted IECs (Fig. 6b), suggesting a possible defect of autophagy in the absence of Brg1.
Several lines of evidences indicate that impaired autophagy causes oxidative stress6,16. We therefore reasoned that BRG1 modulated ROS homeostasis through regulation of autophagy. To test this possibility, we isolated IECs from the colons of 2-month-old Brg1flox/flox and VillinCre-ERT2; Brg1flox/flox or Rosa26Brg1/+ and Brg1IEC-OE/+ mice. After 4 days of culturing, western blotting analysis revealed that the BRG1-depleted IECs (by treatment of 4-OHT) exhibited a profound reduction in membrane-bound LC3-II (LC3B-I to LC3B-II conversion) and an increase in the cellular levels of the autophagic substrate p62 (Fig. 6c). Conversely, IECs bearing BRG1 overexpression displayed an enhanced LC3-I/II conversion and a simultaneously decreased p62 level (Fig. 6c). In addition, the impaired autophagy was also supported by intestinal organoid culture assay. As reflected by L3II conversion and p62 level, Brg1 deletion led to a reduction of autophagy (Supplementary Fig. 5c). Further transmission electron microscopy assays verified that the number of autophagosomes was reduced in the colons following 1 week of Brg1 deletion as compared with that in controls (Fig. 6d). To ensure this observation, we generated Brg1-deficient autophagic reporter mice (Brg1IEC-AKO; LC3-GFP) and detected a significant decrease in the number of LC3-GFP puncta in the colons of 7-week-old Brg1IEC-AKO mice (1 week after Brg1 ablation; Fig. 6e). Importantly, the cell intrinsic requirement of Brg1 to govern autophagy was supported by IEC culture assay. As reflected by the number of LC3 puncta, L3II conversion, and p62 level, Brg1 deletion led to a gradual reduction of autophagy in a time course dependent on Brg1 deletion (Fig. 6f, g). As LC3II accumulation is attributed to either increased autophagy induction or impaired autophagosome turnover, the effects of Brg1 loss on autophagic flux were evaluated in the presence of chloroquine (CQ), an inhibitor of lysosomal degradation. We observed that LC3II levels in the presence of CQ were persistently reduced in Brg1-depleted IECs (Fig. 6h–i). Thus, these results indicate that BRG1 is required for autophagic induction in the colonic epithelium. Next, we aimed to clarify whether defects of autophagy indeed contributed to uncontrolled ROS reactions in Brg1-deficient IECs. Treatment with rapamycin to enhance autophagy in Brg1-depleted IECs upregulated the expression levels of the key autophagy regulators, and led to the levels of ROS and cell death comparable to those observed in the IECBrg1-F/F cells (Supplementary Fig. 5d–g), suggesting that Brg1 loss impairs autophagy and thereby enhances ROS productions.
To distinguish between BRG1 binding sites and BRG1 functional sites genome-wide, we performed H3K9ac (a histone marker of active gene transcription) ChIP-seq in Brg1F/F and Brg1IEC-AKO IECs. The ChIP-seq analysis revealed that 12573 genes possessed H3K9ac occupancies within 6 kb of annotated genes (Supplementary Fig. 5h). The Venn diagrams indicated that there were still 685 genes overlapped (Fig. 6j). GO term analysis identified Autophagic vacuole fusion and Autophagic vacuole assembly pathways enriched in the 685 genes (Supplementary Fig. 5i). To define the regulatory mechanism by which BRG1 controlled autophagy, we referenced the express profiles and ChIP-seq results, and examined expression levels of key autophagy-regulatory genes including Atg16l1, Wipi2, Atg7, and Ambra1. As expected, BRG1 loss and overexpression indeed down- and upregulated their expression levels in the IECs, respectively (Fig. 6k). Direct BRG1 and H3K9ac occupancies within the candidate gene loci were also seen in Genome Browser tracks (Fig. 6l, Supplementary Fig. 5j) and readily validated by the ChIP-qPCR assays (Fig. 6m). Consistent with the decreased BRG1 recruitment to these gene loci, H3K9ac was simultaneously reduced in the Brg1-depleted IECs (Fig. 6m). Conversely, BRG1 overexpression enhanced the H3K9ac signals within the promoter regions of the Atg16l1, Wipi2, Atg7, and Ambra1 gene loci (Fig. 6m). Thus, Brg1 loss led to a repressive chromatin status that directly repressed the transcription of the genes important for autophagosome initiation. Consistent with the GEM results, we found positive associations between BRG1 and ATG16L1, WIPI2, and AMBRA1 in the IBD biopsies (using datasets from GSE57945; Supplementary Fig. 5k). Together, our results indicate that BRG1 modulates the multifaceted autophagy machinery to govern colon homeostasis.
BRG1 regulates autophagy to control ROS reactions in IECs
Given the functional and clinical importance of ATG16L1 in autophagosome formations and colitis11,19, we assessed whether the downregulation of Atg16l1 in Brg1-deleted IECs indeed caused the uncontrolled ROS reactions and the defects in cell survival. Thus, we used the oligos to knockdown (KD) Atg16l1 in IECBrg1-F/F and IECBrg1-F/F;CreERT2. As expected, Atg16l1 ablation in IECBrg1-F/F greatly reduced the LC3I/II conversion, and meanwhile enhanced ROS and cleaved caspase-3 signals (Fig. 7a, b). Importantly, Atg16l1 KD in Brg1-deficient IECs did not further reduce the autophagy response. The cells with or without BRG1 ablation exhibited a similar extent of ROS elevation as well as the cleaved caspase-3 level (Fig. 7a, b). Restoration of ATG16L1 in Brg1/Atg16l1-depleted cells largely alleviated the overproductions of ROS and improved the cellular survival as compared with Brg1-deleted IECs (Fig. 7a, b). Together, these results highlight the requirement of Brg1 for the regulation of Atg16l1 or autophagy to modulate ROS homeostasis in IECs.
Besides Atg16l1, we showed that BRG1 directly regulated Wipi2, Atg7, and Ambra1, which are also important for autophagosome biogenesis. To further clarify the functional dependence between Brg1 and autophagy in colonic inflammation, we generated VillinCre/+; Atg5flox/flox mice that conditionally ablated the autophagy protein ATG5 in the IECs (Atg5IEC−/−) (Fig. 7c). Upon treatment with 3% DSS, compared with the littermate controls, the Atg5IEC−/− mice exhibited a greater weight loss, enhanced colon length shortening, and immunopathology (Fig. 7d–f), confirming the indispensable role of autophagy in resolving gut inflammation. More importantly, we showed that the Atg5 ablation in the Brg1IEC-OE/+ mice compromised the protective role of BRG1 overexpression against the DSS treatments. As reflected by the body weight loss, colon length and histological examinations, the Brg1IEC-OE/+; Atg5IEC−/− mice exhibited epithelial erosion and immune cell infiltration comparable to those in the Atg5IEC−/− mice (Fig. 7d–f). In addition, depletion of Atg5 in the Brg1IEC-OE/+ mice greatly enhanced the inflammatory cytokine, 8-OHdG and ROS production to the levels similar as those observed in the Atg5IEC−/− mice (Fig. 7g, h; Supplementary Fig. 6a). Meanwhile, the Atg5 ablation in the Brg1IEC-OE/+ mice led to severe barrier disruption and epithelial cell death comparable to those in the Atg5IEC−/− mice (Supplementary Fig. 6b–e). Thus, defective autophagy in Atg5-deficient mice resulted in excess ROS, which led to the defects in cellular apoptosis and barrier integrity, and the subsequent inflammation. Altogether, the GEMs indicate that Brg1 prevents colon inflammation dependent on the regulation of the autophagy to restrain ROS over-reactions.
The intestinal microbiota plays an important role in driving inflammatory responses during disease development and progression43,44,45. To rule out the possibility that the gut microbiota contributes to intestinal barrier damage caused by BRG1 deficiency, we generated gut microbiota-depleted mice by treating Brg1IEC-AKO and Brg1F/F mice with drinking water containing an antibiotic cocktail for 3 weeks and then treated them with 1%DSS. The depletion of gut microbiota was confirmed by performing 16S rDNA sequencing. The successful depletion of the gut microbiota was evident as no sufficient bacterial diversity and microbiota composition were observed (Supplementary Fig. 7a–c). As compared with the Brg1F/F mice, there was less bacterial diversity but unchanged gut microbiota composition in untreated Brg1IEC-AKO mice (Supplementary Fig. 7a–c). Interestingly, depletion of the gut microbiota by antibiotics reduced expression of proinflammatory cytokines and chemokines of Brg1IEC-AKO mice comparable to those observed in the Brg1F/F mice (Supplementary Fig. 7d). However, antibiotic-treated Brg1IEC-AKO mice still exhibited more severe barrier disruption, epithelial cell apoptosis, impaired autophagy, and oxidative stress than Brg1F/F mice (Supplementary Fig. 7e–i). These results suggested that depletion of the gut microbiota did not facilitate the recovery of intestinal barrier in Brg1IEC-AKO mice. Thus, the gut microbiota does not contribute to intestinal barrier disruption caused by BRG1 deficiency. Altogether, BRG1 protects the colon from inflammatory insults via a mechanism dependent on autophagy and ROS sequestration (Fig. 7i).
Discussion
Autophagy, a system for sensing and adapting to environmental changes, is intimately involved in cellular defense, microbial tolerance, and metabolic control10,11,12. Despite recent progress, the underlying mechanism by which this degradative process is balanced remains unclear. Here, we showed that multifaceted autophagy-component genes, including Atg16l1, Ambra1, Wipi2, and Atg7, are directly controlled by BRG1 in the colons. ATG16L1 and ATG12-ATG5 complex formation is known to define the site for LC3 PE conjugation and facilitate autophagosome formation11,46. Ambra1 interacts with Beclin1 through the target lipid kinase Vps34/PI3KC3 to assemble a class III PI3K complex, which positively regulates the formation of autophagosomes47,48. In addition, WIPI2 is a PtdIns(3)P effector upstream of ATG16L1 that is required for LC3 conjugation49,50. Thus, our results demonstrated that BRG1 is a key regulator controlling autophagosome biogenesis and therefore highlight the homeostatic function of BRG1 in colons.
Mammalian cells are consistently exposed to ROS generated from either endogenous metabolism or environmental oxidants51,52. We found that Brg1 loss in adult mice leads to ROS accumulations, and thereby enhances epithelium death and barrier integrity. This finding is further supported by the antioxidant NAC treatment, which attenuates the ROS reactions and relieves the colitis symptoms in the Brg1IEC-AKO mice. Thus, aberrant ROS accumulation is mainly responsible for the chronic inflammation observed in the Brg1IEC-AKO mice. Autophagy has been considered the main mechanism responsible for removing oxidized proteins in cells11,13. In the intestines, defects in autophagy, such as Atg16l1 and Atg5 ablation, stimulate ROS reactions6,11,53. The current studies utilize GEMs and cell cultures to clarify that BRG1 attenuated colonic inflammation through autophagy-dependent oxidative stress. We showed that Atg5 depletion in the Brg1IEC-OE/+ mice compromises the protective effects elicited by the BRG1 overexpression and enhances the ROS levels to those observed in the Atg5IEC−/− mice. Conversely, restoration of Atg16l1 or the treatment with rapamycin in the Brg1-depleted IECs reduces the levels of ROS and improved epithelial cell survival. Thus, adult BRG1 protects the colon from inflammatory insults via a mechanism dependent on autophagy and ROS sequestration (Fig. 7i).
Unresolved tissue injury during inflammation inevitably results in tissue neoplastic transformation. Our current study demonstrates that adult Brg1 loss results in compensatory regeneration coupled with ROS-induced DNA damage in an inflammation-context, which promotes the malignant progression of CRC. This finding is further corroborated by the reduction in acute inflammation and tumorigenesis in the BRG1-overexpressing mice. Notably, these results differ from a previous report in which the loss of Brg1 suppresses adenoma formation in an Apc-mutated context34. Regarding the opposing tumorigenic functions in these two models, numerous studies have shown that the functions of the mammalian SWI/SNF enzyme appear to be cell type- and subunit-dependent24,54,55. Thus, unsurprisingly, BRG1 can act as either an oncogene or tumor suppressor in a context-dependent manner.
BRG1 plays a pivotal role in crypt-villous remodeling, differentiation and cell survival in the duodenum of neonatal mice by regulating the Notch signaling36. In the present study, we also examined whether Notch signaling is altered in adult Brg1-depleted colons. However, no appreciable alternations are detected in the Brg1IEC-AKO mice as determined by the expression levels of the Notch ligands Dll1, Dll3, Dll4, Jag1, and Jag2 and the Notch target genes Hes1, Hey1, and Hey2 (Supplementary Fig. 8). Moreover, BRG1 is known to modulate stem cell self-renewal in the small intestines by regulating the Wnt signaling35. We did not observe changes in stem/progenitor cells in the colons before the onset of colitis (Supplementary Fig. 1). In contrast, the numbers of Paneth and goblet cells are reduced in the adult Brg1-depleted mice, whereas these defects are reversed by the NAC treatment. Furthermore, the results obtained from the BRG1 overexpression mice further support the idea that BRG1 is intimately involved in colon epithelial cell homeostasis without altering the differentiation process. However, because BRG1 is a key epigenetic regulator involved in multiple transcriptional processes, we cannot fully exclude the possibility that other signaling changes also contribute to the phenotype observed in the present study. In addition, the underlying mechanism leading to reduced BRG1 expression during chronic inflammation remains to be determined in future studies.
Together, our results highlight the importance that BRG1 functions as a homeostatic regulator that integrates the intact mucosal barrier by modulating autophagy-dependent oxidative stress in the colon (Fig. 7i). Inflammation is closely associated with tumorigenesis, and IBD is a predisposing factor for CRC. Thus, our results establish a role for BRG1 in inflammation-associated CRC and may provide insight into understanding of other human disorders associated with BRG1 deficiency.
Methods
Human specimen analysis
Patients with IBD and non-IBD healthy subjects for this study were recruited from Fudan University Shanghai Cancer Center and Shanghai Tenth People’s Hospital, China40. The study was approved by the ethics committee of the Shanghai Tenth People’s Hospital (SHSY-IEC-pap-16-24). The use of pathological specimens as well as the review of all the pertinent patient records was approved by the institutional ethics review board. Immunohistochemical analyses were performed using a specific anti-BRG1 antibody (Abcam, Cat# ab110641 (1:500))40,56. In brief, protein expression was scored and quantified by pathologists who were blinded to the outcome of the cases, and the quantification was based on a multiplicative index of the average staining intensity (0–3) and the extent of staining (0–3), which yielded a 10-point staining index that ranged from 0 to 9. Tissue RNA from colonic biopsies of IBD patients and heathy controls was also prepared for the analysis of gene expression.
Mice
All mice were maintained in a specific-pathogen-free (SPF) facility and all experimental procedures were approved by the institutional biomedical research ethics committee of the Shanghai Institutes for Biological Sciences or Institute of Zoology, Chinese Academy of Sciences. Brg1IEC-AKO mice were generated by crossing Brg1-floxed mice57 with VillinCre-ERT2 mice (The Jackson Laboratory)38, and tamoxifen was intraperitoneally injected for 3 consecutive days at 100 mg kg−1 body weight. BRG1-overexpressing mice (Brg1IEC-OE/+) were generated by crossing R26Brg1/+ mice56 with VillinCre/+ mice. LC3-GFP mice were purchased from The Jackson Laboratory and Atg5-floxed mouse strain (RBRC02975)58 were purchased from the RIKEN Bio Resource Center with permission from Dr. Noboru Misushima (The University of Tokyo). All the mice were maintained on C57BL/6J background and littermates with the same treatment were used for control experiments. For permeability experiments, 3-month-old mice were fasted for 4 h, and treated with FITC-conjugated dextran (500 mg kg−1 body weight). The fluorescence intensity was determined by FITC-dextran standard curve.
Induction of colitis and CRC
All the mice at 2 months of age were first treated with tamoxifen (100 mg kg−1 body weight) for 3 consecutive days to induce Brg1 deletion, and then received DSS or AOM/DSS treatments as indicated. To induce colitis, mice were fed with 3 or 1% DSS (molecular weight, 36–50 kDa; MP Biomedicals) for 3 or 5 days, followed by regular drinking water, body weight was daily recorded. For AOM alone treatment, Brg1F/F and Brg1IEC-AKO mice were intraperitoneally injected with 10 mg kg−1 AOM (Sigma), and mice were sacrificed 20 weeks later. In AOM/DSS experiments, mice were first treated with a single dose of AOM, and 1 or 3% DSS was given in the drinking water for 3 days, followed by 2 weeks of regular drinking water. The DSS treatment was repeated for two additional cycles, and mice were sacrificed 12 weeks after AOM injection, except when indicated otherwise.
IEC isolation and culture
IECs were isolated from Brg1flox/flox, VillinCre-ERT2; Brg1flox/flox or R26Brg1/+ and Brg1IEC-OE/+ mice, and Brg1 deletion is achieved by 4-OHT (5 μM) treatment in cells. The IECs corresponding to each genotype were referred as IECBrg1-F/F, IECBrg1-F/F; CreERT2 or IECBrg1/+, IECBrg1-OE/+. For RNA-Seq and ChIP-Seq analyses, IECs from colons were isolated using isolation buffer (30 mM EDTA and 1 mM DTT). For culture purpose, the colons were cut into pieces and washed by DMEM for two times, then incubated with digestion buffer (DMEM with collagenase type I and Dispase II) for 2 h in 37 °C. After the incubation, the cell suspension was passed through 100 μm cell strainers (Corning). After washes, the cells were plated in dishes coated with rat tail tendon collagen type I overnight and were cultured in DMEM with 10% FBS and 1% penicillin/streptomycin. The next day, the cells were treated with rapamycin (20 nM) or NAC (5 mM) for subsequent experiments. The purities of colonic epithelial cell were confirmed by FACS analysis of EpCAM staining. For detecting the ROS levels, cultured IECs were digested and centrifuged, the precipitates were resuspended by PBS and incubated with CM-H2DCFDA (5 mM; C6827, Life Technologies) for 10 min in 37 °C and measured by flow cytometry.
Organoid culture and analysis
The intestines were opened longitudinally, and villi were scraped away. After thorough washing in cold PBS, the pieces were incubated in 2 mM EDTA/PBS for 10 min at 4 °C. Then, EDTA solution was replaced with PBS and shacked vigorously for 45 s. Crypt fractions were purified by successive centrifugation steps. Hundred microliters of Advanced DMEM/F12 (Invitrogen) containing growth factors (50 ng ml−1 EGF, PeproTech; 500 ng ml−1 R-spondin, PeproTech and 100 ng ml−1 Noggin; PeproTech) was added and refreshed every 2 or 3 days. 4-OHT was added to medium at a concentration 2 μM after 5 days of organoid culturing. After 48 h, the organoids were stained with 7-AAD for 5 min, and photos were imaged and quantified by Image J software.
RNA-Seq and ChIP-Seq analysis
IECs was isolated from 7-week-old Brg1F/F and Brg1IEC-AKO by EDTA-based isolation. Each sample contained three to five independent repeated animals, and subjected to HiSeq performed by Guangzhou RiboBio Co., Ltd. Paired-end reads were aligned to the mouse reference genome mm10 with HISAT2. HTSeq v0.6.0 was used to count the reads numbers mapped to each gene. The whole samples expression levels were presented as RPKM (expected number of Reads PerKilobase of transcript sequence per Million base pairs sequenced), which is the recommended and most common method to estimate the level of gene expression. The statistically significant DE genes were obtained by an p-value threshold of <0.05 and fold change ≥1.5. All differentially expressed mRNAs were selected for GO analysis which was performed on DAVID (https://david.ncifcrf.gov/). ChIP-Seq analysis was performed by Active Motif, Inc. using an antibody against BRG1 (Abcam) and H3K9Ac (Abcam). Seventy-five-nucleotide reads generated by Illumina sequencing were mapped to the genome using the BWA algorithm with default settings. In total, 26349 peaks were identified over the input control, and the heat maps and average profile for TSS were generated using ngsplot v2.61.
Immunohistochemistry and transmission electron microscopy
Tissues were fixed overnight in 4% paraformaldehyde, prepared using the Swiss roll technique, embedded in paraffin, and cut into 7-μm sections. H&E-stained sections were scored by a pathologist in a blinded fashion. Colitis scores were assigned based on a multiplicative index of severity of inflammation (0–3), ulceration (0–3), and hyperplasia of the mucosa (0–4)59. To quantify goblet cells, PAS+ cells were quantified from five random fields from at least five mice per genotype. To quantify Paneth cells, lysozyme+ cells were quantified from 100 crypts from at least 3 mice per genotype; data are represented as mean ± SEM. Tumor grades were scored according to previous report60. Briefly, low-grade dysplasia consisted of stratified dysplastic epithelium retaining its columnar shape. The neoplastic crypt cells were elongated and crowded, with hyperchromatic nuclei, but maintained polarity with respect to the basement membrane. High-grade dysplasia was characterized by more pronounced nuclear atypia, with loss of epithelial cell nuclear polarity. The neoplastic glands may show architectural complexities such as a cribriform appearance. For each animal, 10 random lesions (hyperplasia, LG dysplasia or HG dysplasia) were recorded for the quantifications. Thus, the numbers of each subtype of lesions in each experimental group (n = 10 per genotype) were established and the percentages of different subtypes of lesions were compared. The statistical significance between groups was determined by the chi-square test. Primary antibodies used for IHC were as follows: anti-Ki67 (B56), BD Biosciences, Cat# 550609 (1:500); anti-lysosome, DAKO, Cat#A0099 (1:500); anti-8-OHdG, Abcam, Cat# ab48508 (1:500); anti-cleaved caspase-3, Cell Signaling Technology, Cat# 9661 (1:800); anti-E-cadherin, Cell Signaling Technology, Cat#3195T (1:400); and anti-ZO-1, Invitrogen, Cat# 40-2200 (1:500). Biotinylated secondary antibodies were purchased from Jackson Immunology. Staining was visualized with ABC Kit Vectastain Elite (Vector Laboratories) and DAB substrate (Vector Laboratories). PAS staining was performed using PAS staining kits (Sigma-Aldrich) and ALP activity assay was performed using the Alkaline Phosphatase Staining Kit (Vector Laboratories) as described in the manufacturer’s protocols. For the analysis of autophagosome by transmission electron microscopy, pieces of colons were fixed at 4 °C in 2.5% glutaraldehyde, post fixed in OsO4 (1%) for 2 h, and then dehydrated through a series of alcohol concentrations, before being progressively embedded in Epon 812 epoxy resin. Micrographs were obtained with a FEI Tecnai G2 Spirit transmission electron microscope.
RT-qPCR and ChIP-qPCR assays
RNA was isolated using TRIzol followed by RQ1 RNase-free DNase Set treatment (Promega) according to the manufacturer’s instructions. First strand cDNA was synthesized using Superscript II (Invitrogen). SYBR Green Master Mix reagents (Roche) and primer mixtures (Supplementary Table 1) were used for the real-time PCR. Student’s t-test was used to statistical analysis and p value <0.05 was considered significant. The ChIP assays were performed using EZ ChIP kit (Millipore). The procedure was as described in the kit provided by the manufacturer. Briefly, isolated IEC cells were fixed by 1% formaldehyde, fragmented by sonication. BRG1 (Abcam, Cat# ab110641) (2 μg 50 μL−1) and H3K9Ac (Abcam, Cat# 4441) (2 μg 50 μL−1) were then used for immunoprecipitation. After washing and reverse-crosslinking, the precipitated DNA was amplified by primers and quantified by the qPCR. Primer sequences can be found in the Supplementary Table 1.
Immunoblotting
The primary antibodies used in this study were as follows: anti-BRG1 (EPNCIR111A) Abcam Cat# ab110641 (1:10,000); anti-Caspase3 (8G10), Cell Signaling Technology, Cat# 9665 (1:1000); anti-C-Caspase 3, Cell Signaling Technology, Cat# 9661 (1:1000); anti-PARP (46D11), Cell Signaling Technology, Cat# 9532 (1:1000); anti-Ki67 (B56), BD Biosciences, Cat# 550609 (1:500); anti-EpCAM (G8.8), BD Biosciences, Cat# 552370 (1:500); anti-ZO1, Invitrogen, Cat# 40-2200 (1:500); anti-8-OHd G, Abcam, Cat# ab48508 (1:500); anti-LC3A/B (D3U4C), Cell Signaling Technology, Cat# 12741 (1:1000); anti-ATG16L1 (D6A5), Cell Signaling Technology, Cat# 8089 (1:1000); anti-PCNA, Santa Cruz Biotechnology, Cat# SC-7909 (1:1000); anti-P-H3, Cell Signaling Technology, Cat# 9701 (1:1000); anti-E-Cadherin, Cell Signaling Technology, Cat# 3195T (1:1000); anti-DCLK1, Abcam, Cat# ab31704 (1:500); anti-Claudin1, Cell Signaling Technology, Cat# 4933T (1:1000); anti-ChgA, Abcam, Cat# ab715 (1:1000); anti-Hes1, Abcam, Cat# ab71559 (1:500). Raw data of immunoblotting can be found in the source data file.
FACS
Cell suspensions were subjected to flow cytometry analyses61. For gating strategy, first FSC/SSC was applied to gate the live cells and then according to fluorochrome to make the subsequent gates. All the samples in the same experiments and comparisons were gated under the same parameters. The antibodies used in this study were as follows: anti-CD11b-APC, eBioscience, Cat# 47-0112-82 (1:400); anti-F4/80-PE, eBioscience, Cat# 25-4801-82 (1:400); anti-CD4-FITC, eBioscience, Cat# 11-5040-41 (1:400); Gr-1-FITC, eBioscience, Cat# 11-0114-82 (1:400).
Isolation of lamina propria cells and analysis
Colons were cut into small pieces and then incubated with RPMI medium supplemented with FBS, 0.5 mM DTT, 5 mM EDTA, and antibiotics at 37 °C for 30 min. After removal of the epithelial layer, the remaining colon segments were incubated at 37 °C with RPMI medium containing 0.5% collagenase D (Roche) and 0.05% DNase (Roche) for 30 min. Lamina propria cells were stained for surface markers CD4, CD11b, F4/80, and Gr-1 using CD4-FITC, CD11b-APC, F4/80-PE, and Gr-1-FITC antibodies, respectively.
Analysis of ROS signatures and autophagy in patients
Analysis in human IBD datasets was carried out essentially as previously described40. The ROS and BRG1signature were derived from GSE42476 and our own dataset. In order to define the degree of gene signature manifestation within profiles from external IBD datasets (e.g., GEO GSE11223), we used the previously described t-score metric40, which was defined for each external profile as the two-sided t-statistic comparing the average of the BRG1-induced genes with the average of the BRG1-repressed genes (genes within the human dataset were first centered to SD from the median of the specimens). For a given dataset, the t-score contrasted the patterns of the BRG1-induced genes with those of the BRG1-repressed genes to derive a single value denoting coordinate expression of the two gene sets. The correlation between BRG1 and ATG16L1, WIPI2b or AMBRA1 mRNA in IBD specimens (GSE57945, n = 38) is computed by nonparametric Spearman correlation.
Statistical analysis
All experiments were performed using 3–15 mice or at least three independent repeated experiments. Unless otherwise indicated, data presented as the mean ± S.E.M. and statistical significance was determined by a two-tailed Student’s t-test. Pearson correlation coefficients were used to evaluate the relationships between BRG1 and gene expressions. χ2 test were used to determine whether there was a significant difference between the expected frequencies and the observed frequencies in one or more categories. *p < 0.05, **p < 0.01, and ***p < 0.001.
Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
The authors declare that all data supporting the findings in this study are available within the paper, Supplementary information and Source data. All data are available from the authors upon reasonable request. RNA-Seq and ChIP-Seq raw data have been deposited in the Gene Expression Omnibus (GEO) under accession number GEO: GSE112128 and GSE135041.
References
Ekbom, A., Helmick, C., Zack, M. & Adami, H. O. Ulcerative colitis and colorectal cancer. A population-based study. New Engl. J. Med. 323, 1228–1233 (1990).
Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140, 883–899 (2010).
Turner, J. R. Intestinal mucosal barrier function in health and disease. Nat. Rev. Immunol. 9, 799–809 (2009).
Alenghat, T. et al. Histone deacetylase 3 coordinates commensal-bacteria-dependent intestinal homeostasis. Nature 504, 153–157 (2013).
Edelblum, K. L. & Turner, J. R. The tight junction in inflammatory disease: communication breakdown. Curr. Opin. Pharmacol. 9, 715–720 (2009).
Ravindran, R. et al. The amino acid sensor GCN2 controls gut inflammation by inhibiting inflammasome activation. Nature 531, 523–527 (2016).
Rescigno, M. The intestinal epithelial barrier in the control of homeostasis and immunity. Trends Immunol. 32, 256–264 (2011).
Takahashi, N. et al. RIPK1 ensures intestinal homeostasis by protecting the epithelium against apoptosis. Nature 513, 95–99 (2014).
Pulendran, B. The varieties of immunological experience: of pathogens, stress, and dendritic cells. Annu. Rev. Immunol. 33, 563–606 (2015).
Zhong, Z., Sanchez-Lopez, E. & Karin, M. Autophagy, inflammation, and immunity: a troika governing cancer and its treatment. Cell 166, 288–298 (2016).
Cadwell, K. et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 456, 259–263 (2008).
Rabinowitz, J. D. & White, E. Autophagy and metabolism. Science 330, 1344–1348 (2010).
Mizushima, N. & Komatsu, M. Autophagy: renovation of cells and tissues. Cell 147, 728–741 (2011).
White, E. The role for autophagy in cancer. J. Clin. Invest. 125, 42–46 (2015).
Wlodarska, M. et al. NLRP6 inflammasome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretion. Cell 156, 1045–1059 (2014).
Patel, K. K. et al. Autophagy proteins control goblet cell function by potentiating reactive oxygen species production. EMBO J. 32, 3130–3144 (2013).
Bretin, A. et al. Activation of the EIF2AK4-EIF2A/eIF2alpha-ATF4 pathway triggers autophagy response to Crohn disease-associated adherent-invasive Escherichia coli infection. Autophagy 12, 770–783 (2016).
Adolph, T. E. et al. Paneth cells as a site of origin for intestinal inflammation. Nature 503, 272–276 (2013).
Hampe, J. et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat. Genet. 39, 207–211 (2007).
Hugot, J. P. et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 411, 599–603 (2001).
Parkes, M. et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn’s disease susceptibility. Nat. Genet. 39, 830–832 (2007).
Sakamaki, J. I. et al. Bromodomain protein BRD4 is a transcriptional repressor of autophagy and lysosomal function. Mol. Cell 66, 517–532 e519 (2017).
Wei, F. Z. et al. Epigenetic regulation of autophagy by the methyltransferase EZH2 through an MTOR-dependent pathway. Autophagy 11, 2309–2322 (2015).
Wilson, B. G. & Roberts, C. W. SWI/SNF nucleosome remodellers and cancer. Nat. Rev. Cancer 11, 481–492 (2011).
Hargreaves, D. C. & Crabtree, G. R. ATP-dependent chromatin remodeling: genetics, genomics and mechanisms. Cell Res. 21, 396–420 (2011).
Hang, C. T. et al. Chromatin regulation by Brg1 underlies heart muscle development and disease. Nature 466, 62–67 (2010).
Davis, R. B., Curtis, C. D. & Griffin, C. T. BRG1 promotes COUP-TFII expression and venous specification during embryonic vascular development. Development 140, 1272–1281 (2013).
Witkowski, L. et al. Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nat. Genet. 46, 438–443 (2014).
Helming, K. C., Wang, X. & Roberts, C. W. M. Vulnerabilities of mutant SWI/SNF complexes in cancer. Cancer Cell. 26, 309–317 (2014).
Reisman, D. N., Sciarrotta, J., Wang, W., Funkhouser, W. K. & Weissman, B. E. Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Res. 63, 560–566 (2003).
Jubierre, L. et al. BRG1/SMARCA4 is essential for neuroblastoma cell viability through modulation of cell death and survival pathways. Oncogene 35, 5179–5190 (2016).
Shi, J. et al. Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation. Genes Dev. 27, 2648–2662 (2013).
Romero, O. A. et al. MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1. Cancer Disco. 4, 292–303 (2014).
Holik, A. Z. et al. Brg1 loss attenuates aberrant wnt-signalling and prevents wnt-dependent tumourigenesis in the murine small intestine. PLoS. Genet. 10, e1004453 (2014).
Holik, A. Z. et al. Brg1 is required for stem cell maintenance in the murine intestinal epithelium in a tissue-specific manner. Stem Cells 31, 2457–2466 (2013).
Takada, Y., Fukuda, A., Chiba, T. & Seno, H. Brg1 plays an essential role in development and homeostasis of the duodenum through regulation of Notch signaling. Development 143, 3532–3539 (2016).
Chakrabarty, S. et al. Targeted sequencing-based analyses of candidate gene variants in ulcerative colitis-associated colorectal neoplasia. Brit J. Cancer 117, 136–143 (2017).
el Marjou, F. et al. Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis 39, 186–193 (2004).
Ireland, H., Houghton, C., Howard, L. & Winton, D. J. Cellular inheritance of a Cre-activated reporter gene to determine Paneth cell longevity in the murine small intestine. Dev. Dynam 233, 1332–1336 (2005).
Liu, Y. et al. Epithelial EZH2 serves as an epigenetic determinant in experimental colitis by inhibiting TNFalpha-mediated inflammation and apoptosis. Proc. Natl Acad. Sci. USA 114, E3796–E3805 (2017).
Gunther, C., Neumann, H., Neurath, M. F. & Becker, C. Apoptosis, necrosis and necroptosis: cell death regulation in the intestinal epithelium. Gut 62, 1062–1071 (2013).
Barrett, C. W. et al. Selenoprotein P influences colitis-induced tumorigenesis by mediating stemness and oxidative damage. J. Clin. Invest. 125, 2646–2660 (2015).
Belkaid, Y. & Hand, T. W. Role of the microbiota in immunity and inflammation. Cell 157, 121–141 (2014).
Joossens, M. et al. Dysbiosis of the faecal microbiota in patients with Crohn’s disease and their unaffected relatives. Gut 60, 631–637 (2011).
Xavier, R. J. & Podolsky, D. K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448, 427–434 (2007).
Moreau, K., Ravikumar, B., Renna, M., Puri, C. & Rubinsztein, D. C. Autophagosome precursor maturation requires homotypic fusion. Cell 146, 303–317 (2011).
Fimia, G. M., Di Bartolomeo, S., Piacentini, M. & Cecconi, F. Unleashing the Ambra1-Beclin 1 complex from dynein chains: Ulk1 sets Ambra1 free to induce autophagy. Autophagy 7, 115–117 (2011).
Di Bartolomeo, S. et al. The dynamic interaction of AMBRA1 with the dynein motor complex regulates mammalian autophagy. J. Cell. Biol. 191, 155–168 (2010).
Dooley, H. C. et al. WIPI2 links LC3 conjugation with PI3P, autophagosome formation, and pathogen clearance by recruiting Atg12-5-16L1. Mol. Cell 55, 238–252 (2014).
Dooley, H. C., Wilson, M. I. & Tooze, S. A. WIPI2B links PtdIns3P to LC3 lipidation through binding ATG16L1. Autophagy 11, 190–191 (2015).
Shadel, G. S., Horvath, T. L. & Mitochondrial, R. O. S. signaling in organismal homeostasis. Cell 163, 560–569 (2015).
Noubade, R. et al. NRROS negatively regulates reactive oxygen species during host defence and autoimmunity. Nature 509, 235–239 (2014).
Thachil, E. et al. Abnormal activation of autophagy-induced crinophagy in Paneth cells from patients with Crohn’s disease. Gastroenterology 142, 1097–1099 (2012).
Roy, N. et al. Brg1 promotes both tumor-suppressive and oncogenic activities at distinct stages of pancreatic cancer formation. Genes Dev. 29, 658–671 (2015).
Von Figura, G. et al. The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma. Nat. Cell Biol. 16, 255–267 (2014).
Li, N. et al. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis. J. Clin. Invest. 127, 1284–1302 (2017).
Sumi-Ichinose, C., Ichinose, H., Metzger, D. & Chambon, P. SNF2beta-BRG1 is essential for the viability of F9 murine embryonal carcinoma cells. Mol. Cell. Biol. 17, 5976–5986 (1997).
Hara, T. et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 441, 885–889 (2006).
Council, N. R. Guide for the Care and Use of Laboratory Animals. 8th edition (National Academy Press, Washington, DC, 2011).
Boivin, G. P. et al. Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology 124, 762–777 (2003).
Xiao, Y. et al. Peli1 promotes microglia-mediated CNS inflammation by regulating Traf3 degradation. Nat. Med. 19, 595–602 (2013).
Acknowledgements
This study was supported by funds from Ministry of Science and Technology of the People’s Republic of China (2017YFA0102900 to W.Q.G.), National Natural Science Foundation of China (81872406 and 81630073 to W.Q.G., 81772938 to L.L.), State Key Laboratory of Oncogenes and Related Genes (KF01801 to L.L.), Science and Technology Commission of Shanghai Municipality (16JC1405700 to W.Q.G., 18140902700 and 19140905500 to L.L.), High Peak IV fund from Education Commission of Shanghai Municipality on Stem Cell Research (to W.Q.G.), KC Wong foundation (to W.Q.G.). L.L. is supported by Innovation Research Plan from Shanghai Municipal Education Commission (ZXGF082101), and Shanghai Jiao Tong University Medical Engineering Cross Fund (YG2016MS52). The study is also supported by Bio-ID Center, School of Biomedical Engineering, Shanghai Jiao Tong University.
Author information
Authors and Affiliations
Contributions
W.Q.G. and L.L. conceived and designed the experimental approach, and W.Q.G., L.L., and M.L. prepared the manuscript. M.L. and T.S. performed most experiments. N.L. contributed to the computational analysis in the statistical analysis. J.P. and D.F. performed the tissue microarray and pathology analyses. W.L. performed and supervised a specific subset of the experiments and analyses.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Peer review information Nature Communications thanks Yoku Hayakawa, Simon Wilkinson and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Source data
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Liu, M., Sun, T., Li, N. et al. BRG1 attenuates colonic inflammation and tumorigenesis through autophagy-dependent oxidative stress sequestration. Nat Commun 10, 4614 (2019). https://doi.org/10.1038/s41467-019-12573-z
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41467-019-12573-z
This article is cited by
-
AMBRA1 promotes intestinal inflammation by antagonizing PP4R1/PP4c mediated IKK dephosphorylation in an autophagy-independent manner
Cell Death & Differentiation (2024)
-
BRG1 Deficiency Promotes Cardiomyocyte Inflammation and Apoptosis by Activating the cGAS-STING Signaling in Diabetic Cardiomyopathy
Inflammation (2024)
-
The SMARCA4R1157W mutation facilitates chromatin remodeling and confers PRMT1/SMARCA4 inhibitors sensitivity in colorectal cancer
npj Precision Oncology (2023)
-
ATP-dependent chromatin remodelers and aging
The Nucleus (2021)
-
PRMT1-mediated H4R3me2a recruits SMARCA4 to promote colorectal cancer progression by enhancing EGFR signaling
Genome Medicine (2021)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.